Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Director | June 22, 2018 | June 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,466 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 9,480 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 9,466 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
OncoMed Pharmaceuticals Inc
Report date June 22, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2028-06-22 | Direct | 15,000 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 1,382,272 · Balance 228,750 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 151,875 · Balance 76,875 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Row 3 · 2026-09-23 · Disposition to issuer · Disposed 76,875 · Balance 0 F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. |
| Ordinary SharesSEC Table I · non-derivative | IndirectAs Custodian | 0 |
Reported balance
After 2026-09-23 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-23 · Disposition to issuer · Disposed 23,400 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2026-09-23 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-23 · Disposition to issuer · Disposed 92,567 · Balance 0 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.24 · Expires 2032-02-24 | Direct | 0 |
Reported balance
After 2026-09-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-23 · Disposition to issuer · Disposed 515,000 · Balance 0 F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.
F4: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerShare Option (Right to Buy) · Derivative | 515,000 | Not disclosed Strike: $10.24 | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · derivative · entry 6 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 515,000 shares Expires 2032-02-24 F4 · price: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 92,567 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 5 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 23,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 4 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian Disclosed balance after: 0 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 76,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 3 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 151,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,875 F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 1,382,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001302443-26-000018 · form4-09252026_120938.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,750 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 14 | $244.64 | $3,425.02 |
DisclosureSEC source: 0001302443-26-000015 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,466 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,692 | $241.39 | $408,431.88 |
DisclosureSEC source: 0001302443-26-000015 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,480 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 20,034 | $16.95 | $339,576.30 |
DisclosureSEC source: 0001302443-26-000012 · form4-08242026_100811.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,611,022 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001302443-26-000010 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,172 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $138.08 | $0.00 |
DisclosureSEC source: 0001302443-26-000008 · edgardoc.xml · derivative · entry 3 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,415 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This non-qualified stock option was granted on August 11, 2016 and vested over a period of one year from September 1, 2016. The options were fully vested as of August 1, 2017. Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,741 | $241.57 | $662,143.37 |
DisclosureSEC source: 0001302443-26-000008 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,567 Read SEC document |
| May 22, 2026 Filed May 27, 2026 22:13 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 3,415 | $138.08 | $471,543.20 |
DisclosureSEC source: 0001302443-26-000008 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 20,038 | $16.55 | $331,628.90 |
DisclosureSEC source: 0001302443-26-000006 · form4-05222026_100553.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,631,056 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001302443-26-000004 · form4-04032026_100419.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,651,094 Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 00:43 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 74,975 | $19.66 | $1,474,008.50 |
DisclosureSEC source: 0001302443-26-000002 · form4-02252026_120248.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,576,094 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2025 Filed Nov 22, 2025 00:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 56,817 | $17.90 | $1,017,024.30 |
DisclosureSEC source: 0001302443-25-000008 · form4-11222025_121129.xml · nonDerivative · entry 3 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,651,069 F3 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 00:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001302443-25-000008 · form4-11222025_121129.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian Disclosed balance after: 23,400 F1 · shares: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. F2 · ownership.nature: The shares are held for grandchildren of the Reporting Person through a UTMA account, for which the Reporting Person serves as custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his grandchildren's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 19, 2025 Filed Nov 22, 2025 00:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001302443-25-000008 · form4-11222025_121129.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,707,886 F1 · shares: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 22:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 5,500 | $180.86 | $994,728.35 |
DisclosureSEC source: 0001302443-25-000006 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,893 Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 22:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,394 | $13.39 | $206,125.66 |
DisclosureSEC source: 0001415889-25-022803 · form4-08222025_100815.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,717,786 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,805 | $111.25 | $200,810.58 |
DisclosureSEC source: 0001765581-25-000078 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,393 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000078 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,198 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-018221 · form4-06252025_100657.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,733,180 F1 · shares: Bona Fide Gift. No compensation was given to the donor for the gifting of shares. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 22:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 9,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017585 · form4-06172025_100629.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian Disclosed balance after: 13,500 F1 · shares: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. F2 · ownership.nature: The shares are held for grandchildren of the Reporting Person through a UTMA account, for which the Reporting Person serves as custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his grandchildren's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 22:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 9,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017585 · form4-06172025_100629.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,753,180 F1 · shares: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. Read SEC document |
| May 20, 2025 Filed May 22, 2025 22:44 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,364 | $9.45 | $145,189.80 |
DisclosureSEC source: 0001415889-25-014263 · form4-05222025_100552.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,762,780 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 2,178 | $9.35 | $20,364.30 |
DisclosureSEC source: 0001415889-25-006684 · form4-03042025_110318.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,778,144 F1 · kind: Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on February 28, 2025. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 00:32 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 35,129 | $9.66 | $339,346.14 |
DisclosureSEC source: 0001415889-25-005357 · form4-02252025_120241.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,775,966 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,997 | $9.97 | $159,490.09 |
DisclosureSEC source: 0001415889-24-027573 · form4-11222024_111145.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,811,095 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 14, 2024 Filed Nov 20, 2024 02:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 3,193 | $9.57 | $30,557.01 |
DisclosureSEC source: 0001415889-24-027297 · form4-11202024_021133.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,827,092 F1 · kind: This transaction is being reported late due to inadvertent administrative error. Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on November 14, 2024. Transaction was with the Issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 00:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,997 | $8.22 | $131,495.34 |
DisclosureSEC source: 0001415889-24-022092 · form4-08232024_120807.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,823,899 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 07, 2024 Filed Aug 9, 2024 22:05 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 3,252 | $7.83 | $25,463.16 |
DisclosureSEC source: 0001415889-24-021057 · form4-08092024_100810.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,839,896 F1 · kind: Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on August 7, 2024. Transaction was with the Issuer and did not involve an open market transaction. Read SEC document |
| August 06, 2024 Filed Aug 6, 2024 22:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,484 | $111.35 | $165,243.40 |
DisclosureSEC source: 0001765581-24-000079 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,691 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 22:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000079 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,175 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,997 | $9.10 | $145,572.70 |
DisclosureSEC source: 0001415889-24-014141 · form4-05222024_100514.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,836,644 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 15, 2024 Filed May 17, 2024 22:01 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 2,068 | $9.85 | $20,369.80 |
DisclosureSEC source: 0001415889-24-013612 · form4-05172024_100519.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,852,641 F1 · kind: Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on May 15, 2024. Transaction was with the Issuer and did not involve an open market transaction. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010328 · form4-04042024_100427.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,850,573 F1 · shares: On April 2, 2024, the reporting person was granted 300,000 RSUs. 150,000 RSUs are subject to service-based vesting conditions and the remaining 150,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008630 · form4-03192024_100308.xml · nonDerivative · entry 4 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian Disclosed balance after: 3,900 F3 · kind: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. F4 · ownership.nature: The shares are held for grandchildren of the Reporting Person through a UTMA account, for which the Reporting Person serves as custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his grandchildren's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008630 · form4-03192024_100308.xml · nonDerivative · entry 3 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550,573 F3 · kind: Reflects the gift of shares by the Reporting Person to a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA"), for which the Reporting Person serves as a custodian. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GiftOrdinary Shares | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008630 · form4-03192024_100308.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,554,473 F2 · kind: Bona Fide Gift. No compensation was given to the donor for the gifting of shares. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:06 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 2,704 | $8.64 | $23,362.56 |
DisclosureSEC source: 0001415889-24-008630 · form4-03192024_100308.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,561,473 F1 · kind: Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on March 15, 2024. Transaction was with the Issuer and did not involve an open market transaction. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 01:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 37,196 | $8.92 | $331,788.32 |
DisclosureSEC source: 0001415889-24-004968 · form4-02232024_010235.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558,769 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 23:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,804 | $10.37 | $163,887.48 |
DisclosureSEC source: 0001415889-23-015454 · form4-11222023_111107.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,595,965 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2023 Filed Aug 22, 2023 22:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,804 | $9.70 | $153,298.80 |
DisclosureSEC source: 0001415889-23-012522 · form4-08222023_100811.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,611,769 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 22:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,241 | $138.16 | $171,454.57 |
DisclosureSEC source: 0001765581-23-000094 · edgardoc.xml · nonDerivative · entry 2 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,444 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.77 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 22:08 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000094 · edgardoc.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,685 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document |
| May 20, 2023 Filed May 23, 2023 23:48 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 15,804 | $11.21 | $177,162.84 |
DisclosureSEC source: 0001415889-23-008676 · form4-05232023_110517.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,627,573 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:41 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 330,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004277 · form4-03042023_010303.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,643,377 F1 · shares: On March 1, 2023, the reporting person was granted 330,000 RSUs. 165,000 RSUs are subject to service-based vesting conditions and the remaining 165,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 00:29 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 37,420 | $10.44 | $390,664.80 |
DisclosureSEC source: 0001415889-23-003078 · form4-02232023_120232.xml · nonDerivative · entry 1 Winningham Rick E · CIK 0001302443 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,377 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.